QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ensysce-biosciences-regains-nasdaq-compliance

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company d...

 ensysce-biosciences-renews-collaboration-with-quotient-sciences-to-undertake-the-study-pf614-mpar-102-to-examine-and-evaluate-the-full-commercial-dose-range-of-the-pf614-mpar-drug-product

New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPARSAN DIEGO, CA / ACCE...

 ensysce-biosciences-q1-2024-gaap-eps-055-beats-090-estimate-sales-305722k-miss-400000k-estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $...

 ensysce-biosciences-q4-eps-113-misses-087-estimate-sales-51503k-beat-39000k-estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of...

 ensysce-biosciences-announces-the-co-may-continue-its-listing-on-the-nasdaq-capital-market-tier-with-an-extension-to-may-13-2024-in-order-to-demonstrate-compliance-with-the-equity-requirement-in-listing-rule-5550b1

Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to ...

 ensysce-biosciences-receives-fda-guidance-for-pf614-mpar-program

The meeting focused on the Company's non-clinical program for the combination product that is designed for the treatment of...

 why-amd-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD rep...

Core News & Articles

ENSC: 92% | Ensysce Biosciences Reports Completion Of A Constructive End Of Phase 2 Meeting With FDA Regarding Its Lead 'Ne...

 ensysce-biosciences-reports-completion-of-a-constructive-end-of-phase-2-meeting-with-fda-regarding-its-lead-next-generation-analgesic-pf614-phase-3-program-expected-to-begin-enrollment-in-mid-2024

"We are appreciative of the guidance provided by the FDA to help us properly position PF614 as we progress through clinical...

 ensysce-biosciences-to-present-oral-overdose-protection-for-opioids-at-the-5th-annual-nih-heal-meeting

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC), a clinical-stage biotech company applyin...

 why-blackberry-shares-are-trading-lower-by-over-17-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private ...

 why-netflix-shares-are-trading-higher-by-10-here-are-20-stocks-moving-premarket

Shares of Netflix, Inc. (NASDAQ: NFLX) shares rose sharply in today’s pre-market trading as the company reported better-than-e...